HAS recommendation on Place of Moderna's Spikevax® mRNA vaccine in 12 to 17 year olds - July 28, 2021

The SPIKEVAX® vaccine (Moderna laboratories) obtained a conditional marketing authorization (AMM), in Europe (centralized procedure), on January 6, 2021 "for active immunization for the prevention of COVID-19 caused by SARS-CoV-2 virus, in people aged 18 and over ”, with an extension of its indication to adolescents from 12 to 17 years old on July 23, 2021.

These recommendations are part of an extension of the MA for the mRNA vaccine SPIKEVAX® and therefore aim to clarify its place in the light of vaccine efficacy and safety data in adolescents aged 12 to 17 years.